Market Cap: $10.17B
HI
Halozyme Therapeutics, Inc.
HALO
NASDAQ (NASDAQ Global Select)USD
Market Cap: $10.17B
Halozyme Therapeutics (Ticker: HALO) leverages its innovative ENHANZE technology to transform the delivery of biologic drugs, marking a significant advancement in the pharmaceutical industry. The grow…
Halozyme Therapeutics (Ticker: HALO) indicates it anticipates minimal disruption to its royalty revenues, extending through 2035, following the proposed CMS Medicare Drug Price Negotiation Program. Dr…
Halozyme Therapeutics (Ticker: HALO) continues to advance its innovative position in the biopharmaceutical landscape, particularly following recent developments related to its ENHANZE drug delivery te…
Halozyme Therapeutics (Ticker: HALO) has made a significant stride in the biopharmaceutical industry through a major collaboration with GSK, announced on May 7, 2026. This partnership grants GSK acces…
Halozyme Therapeutics Appoints David Ramsay as Interim CFO Halozyme Therapeutics, Inc. announces the appointment of David Ramsay as Interim Chief Financial Officer (CFO), a decision that looks to bols…
Halozyme Therapeutics Signals Leadership Confidence Amid Insider Sale In a recent disclosure to the Securities and Exchange Commission (SEC), Cortney Caudill, the Senior Vice President of Halozyme The…
Halozyme Therapeutics: Bridging Innovation and Leadership Insight Amid Market Sensitivity Halozyme Therapeutics, a prominent player in the biopharmaceutical landscape, operates at the cutting edge of…
Innovative Technology in Electric Marine Power: Blade Outboards Launches Halo Connect Platform Blade Outboards, committed to revolutionizing marine propulsion with electric technology, introduces the…
Outdoor-styled pet tracker highlights platform and partnership strategies relevant to drug‑delivery firms Lifestyle tie-up around Halo Collar 5 exemplifies how device-plus-software products leverage b…
Halozyme Therapeutics Unveils Innovative Pricing Strategy to Benefit Customers Halozyme Therapeutics, a leader in the biotechnology sector specializing in drug delivery solutions, is making waves with…
Halozyme Therapeutics Advances Customer-Centric Innovation with ARR Milestones Program Halozyme Therapeutics introduces its groundbreaking pricing initiative, the ARR Milestones program, aiming to res…
Halozyme and Skye Bioscience Forge Innovative Collaboration to Combat Obesity Halozyme Therapeutics, Inc. has recently partnered with Skye Bioscience, Inc. in a groundbreaking global collaboration aim…
Oncolytics Biotech's Breakthrough in Gastrointestinal Cancer Treatment Oncolytics Biotech Inc. is poised to revolutionize the treatment landscape for gastrointestinal cancers, especially those traditi…
Oncolytics Biotech: Pioneering New Frontiers in Gastrointestinal Cancer Treatment Oncolytics Biotech Inc. is at the forefront of a transformative shift in the treatment of gastrointestinal cancers, pa…
Halozyme Secures Legal Victory Against Merck in Patent Dispute Halozyme Therapeutics, Inc. announces a significant legal development as a German court issues a preliminary injunction against Merck, pr…
Halozyme Therapeutics: Pioneering Innovations in Drug Delivery Systems Halozyme Therapeutics is at the forefront of transforming drug delivery systems, particularly through its proprietary Enhanze™ te…
Halozyme Therapeutics: Pioneering Advanced Drug Delivery Solutions Halozyme Therapeutics, Inc., a biopharmaceutical leader based in San Diego, is poised to showcase its innovative approaches to drug d…
Halozyme Therapeutics Expands Drug Delivery Capabilities Through Strategic Collaborations Halozyme Therapeutics, Inc. announces a significant global collaboration with Merus N.V. aimed at enhancing ca…
Halozyme Therapeutics Gains FDA Approval for Innovative Treatment in Multiple Myeloma Halozyme Therapeutics, Inc. announces a significant milestone with the FDA approval of DARZALEX Faspro® (daratumum…
Halozyme Therapeutics Secures $1.3 Billion Through Convertible Senior Notes Halozyme Therapeutics, Inc. embarks on a significant financing initiative, announcing the pricing of two series of convertib…
Halozyme Therapeutics Expands Financial Strategy with Convertible Senior Notes Offering Halozyme Therapeutics, Inc. announces a significant move in its financial strategy by offering $650 million in c…
Halozyme Therapeutics Strengthens Financial Position with Convertible Senior Notes Offering Halozyme Therapeutics, Inc. announces its plan to raise $650 million through the issuance of convertible sen…
Halozyme Therapeutics Prepares for Key Earnings Report Amid Product Development Focus Halozyme Therapeutics is on the brink of releasing its quarterly earnings report on November 3, 2025, a moment tha…
Revolutionizing School Transportation: First Student's HALO™ Platform Earns Industry Recognition First Student, a prominent name in the innovative school transportation sector, garners attention with…
First Student Revolutionizes K-12 Transportation with HALO™ Platform First Student, a leader in innovative school transportation, earns the Fast Company’s Next Big Thing in Tech Award for its groundbr…
HALO AirFinance Completes Strategic Financing Initiative in Aviation Sector HALO AirFinance, a joint venture between GA Telesis and Tokyo Century Corporation, achieves a significant milestone in the a…
Halo Collar 5: Revolutionizing Pet Safety with Advanced Technology Halo, a leading innovator in pet safety, introduces the Halo Collar 5, which sets a new standard in GPS tracking technology for dogs.…
Ongoing Threat of Unexploded Ordnance in the Solomon Islands The Solomon Islands continues to grapple with the dangerous legacy of World War II, primarily due to the presence of unexploded ordnance (U…
Halozyme Therapeutics Showcases Innovations in Drug Delivery Technology at Upcoming Investor Conferences Halozyme Therapeutics, Inc. is set to highlight its pioneering advancements in drug delivery te…
Halozyme Therapeutics: A Shift in Investor Sentiment Amidst Decreasing Short Interest Halozyme Therapeutics, a prominent player in the biotechnology sector, experiences a significant decrease in its s…
Halozyme Therapeutics: Pioneering Drug Delivery Solutions in Biopharmaceuticals Halozyme Therapeutics stands out in the biopharmaceutical sector with its innovative approach to drug delivery, an area…
HALO AirFinance Strengthens Aviation Sector with Tailored Financing Solutions In a significant development within the aviation finance sector, HALO AirFinance, a joint venture formed by GA Telesis, LL…
HALO AirFinance Closes Loan for Royal Jordanian Airlines' Fleet Modernization HALO AirFinance, a joint venture between GA Telesis, LLC and Tokyo Century Corporation, marks a significant milestone by s…
Strengthening Aviation Financing: HALO AirFinance Closes Major Loan Facility HALO AirFinance (“HALO”), a collaboration between GA Telesis and Tokyo Century Corporation, successfully completes a senior…
Halozyme Therapeutics: Sustained Growth and Market Resilience Halozyme Therapeutics (HALO) continues to showcase its strength and resilience in the biopharmaceutical industry, consistently outperformi…
Halozyme Therapeutics: Innovations in Drug Delivery Technology Halozyme Therapeutics Inc. is making significant strides in the biotech industry, particularly with its proprietary drug delivery technol…
Halozyme Therapeutics: Advancing Subcutaneous Drug Delivery Systems Halozyme Therapeutics Inc. continues to push the boundaries of drug delivery technology with its innovative subcutaneous delivery sy…
Halozyme Therapeutics Advances in Biopharmaceutical Innovations Halozyme Therapeutics continues to make significant strides in the biopharmaceutical landscape, focusing on its innovative drug delivery…
Advancing Aviation Finance: HALO AirFinance Seals Mezzanine Loan for Boeing 747-8F HALO AirFinance (HALO), a strategic joint venture formed by GA Telesis (GAT) and Tokyo Century Corporation (TC), mark…
HALO AirFinance Strengthens Aviation Financing Portfolio with Innovative Loan Structure HALO AirFinance ("HALO"), a collaborative venture between GA Telesis and Tokyo Century Corporation, successfully…
HALO AirFinance Expands Aviation Financing with Strategic Mezzanine Loan HALO AirFinance, a joint venture between GA Telesis and Tokyo Century Corporation, announces the successful closing of a mezzan…
First Student Unveils HALO™: Transforming Student Transportation Management First Student, a leader in the student transportation sector, introduces HALO™, a groundbreaking technology platform designe…
Revolutionizing Student Transportation: First Student Launches HALO™ Platform First Student, a leading provider of student transportation services, launches HALO™, an innovative technology platform de…
Halozyme Therapeutics Strengthens Market Position with Strategic Refinancing Initiative Halozyme Therapeutics, a key player in the biopharmaceutical sector, takes significant steps to solidify its mar…
Halozyme Therapeutics Strengthens Financial Position with Strategic Refinancing Halozyme Therapeutics, a prominent player in the branded merchandise and corporate apparel sector, announces the success…
HALO's Strategic Refinancing: A Leap Towards Growth and Market Leadership HALO, a frontrunner in branded merchandise and corporate apparel, announces the successful completion of a strategic refinanci…
Trimble Enhances Humanitarian Demining Efforts with Advanced Technology Support In a significant development aimed at improving humanitarian efforts in war-affected regions, Trimble (Nasdaq: TRMB) rei…